Global Overactive Bladder Drug Industry Research Report, Growth Trends and Competitive Analysis 2022-2028

Global Overactive Bladder Drug Industry Research Report, Growth Trends and Competitive Analysis 2022-2028

Table of Contents
1 Report Overview
1.1 Research Scope
1.2 Market Segment by Type
1.2.1 Global Overactive Bladder Drug Market Size Growth Rate by Type (2017 VS 2021 VS 2028)
1.2.2 Anticholinergics
1.2.3 Solifenacin
1.2.4 Oxybutynin
1.2.5 Darifenacin
1.2.6 Fesoterodine
1.2.7 Tolterodine
1.2.8 Trospium
1.2.9 Others
1.3 Market Segment by Application
1.3.1 Global Overactive Bladder Drug Market Share by Application (2017 VS 2021 VS 2028)
1.3.2 Idiopathic Bladder Overactivity
1.3.3 Neurogenic Bladder Overactivity
1.4 Study Objectives
1.5 Years Considered
2 Market Perspective
2.1 Global Overactive Bladder Drug Market Size (2017-2028)
2.1.1 Global Overactive Bladder Drug Revenue (2017-2028)
2.1.2 Global Overactive Bladder Drug Sales (2017-2028)
2.2 Global Overactive Bladder Drug Market Size across Key Geographies Worldwide: 2017 VS 2021 VS 2028
2.2.1 Global Overactive Bladder Drug Sales by Regions (2017-2022)
2.2.2 Global Overactive Bladder Drug Revenue by Regions (2017-2022)
2.3 Global Overactive Bladder Drug Market Size Forecast by Region
2.3.1 Global Overactive Bladder Drug Sales Forecast by Region (2023-2028)
2.3.2 Global Overactive Bladder Drug Revenue Forecast by Region (2023-2028)
2.4 Global Top Overactive Bladder Drug Regions (Countries) Ranking by Market Size
2.5 Overactive Bladder Drug Market Dynamics
2.5.1 Overactive Bladder Drug Market Trends
2.5.2 Overactive Bladder Drug Market Drivers
2.5.3 Overactive Bladder Drug Market Challenges
2.5.4 Overactive Bladder Drug Market Restraints
3 Competitive Landscape by Manufacturers
3.1 Global Top Overactive Bladder Drug Manufacturers by Sales (2017-2022)
3.1.1 Global Overactive Bladder Drug Sales by Manufacturers (2017-2022)
3.1.2 Global Overactive Bladder Drug Sales Market Share by Manufacturers (2017-2022)
3.1.3 Global 5 and 10 Largest Manufacturers by Overactive Bladder Drug Sales in 2021
3.2 Global Top Manufacturers Overactive Bladder Drug by Revenue
3.2.1 Global Overactive Bladder Drug Revenue by Manufacturers (2017-2022)
3.2.2 Top Overactive Bladder Drug Manufacturers Covered: Ranking by Revenue
3.2.3 Global Overactive Bladder Drug Revenue Share by Manufacturers (2017-2022)
3.2.4 Global Overactive Bladder Drug Market Concentration Ratio (CR5 and HHI)
3.3 Global Top Manufacturers by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Overactive Bladder Drug as of 2021)
3.4 Global Overactive Bladder Drug Average Selling Price (ASP) by Manufacturers
3.5 Key Manufacturers Overactive Bladder Drug Plants/Factories Distribution and Area Served
3.6 Date of Key Manufacturers Enter into Overactive Bladder Drug Market
3.7 Key Manufacturers Overactive Bladder Drug Product Offered
3.8 Mergers & Acquisitions, Expansion Plans
4 Global Overactive Bladder Drug Market Size by Type
4.1 Global Overactive Bladder Drug Historic Market Review by Type (2017-2022)
4.1.1 Global Overactive Bladder Drug Sales Market Share by Type (2017-2022)
4.1.2 Global Overactive Bladder Drug Revenue Market Share by Type (2017-2022)
4.1.3 Overactive Bladder Drug Price by Type (2017-2022)
4.2 Global Overactive Bladder Drug Market Estimates and Forecasts by Type (2023-2028)
4.2.1 Global Overactive Bladder Drug Sales Forecast by Type (2023-2028)
4.2.2 Global Overactive Bladder Drug Revenue Forecast by Type (2023-2028)
4.2.3 Overactive Bladder Drug Price Forecast by Type (2023-2028)
5 Global Overactive Bladder Drug Market Size by Application
5.1 Global Overactive Bladder Drug Historic Market Review by Application (2017-2022)
5.1.1 Global Overactive Bladder Drug Sales Market Share by Application (2017-2022)
5.1.2 Global Overactive Bladder Drug Revenue Market Share by Application (2017-2022)
5.1.3 Overactive Bladder Drug Price by Application (2017-2022)
5.2 Global Overactive Bladder Drug Market Estimates and Forecasts by Application (2023-2028)
5.2.1 Global Overactive Bladder Drug Sales Forecast by Application (2023-2028)
5.2.2 Global Overactive Bladder Drug Revenue Forecast by Application (2023-2028)
5.2.3 Overactive Bladder Drug Price Forecast by Application (2023-2028)
6 North America
6.1 North America Overactive Bladder Drug Sales Breakdown by Company
6.1.1 North America Overactive Bladder Drug Sales by Company (2017-2022)
6.1.2 North America Overactive Bladder Drug Revenue by Company (2017-2022)
6.2 North America Overactive Bladder Drug Market Size by Type
6.2.1 North America Overactive Bladder Drug Sales by Type (2017-2028)
6.2.2 North America Overactive Bladder Drug Revenue by Type (2017-2028)
6.3 North America Overactive Bladder Drug Market Size by Application
6.3.1 North America Overactive Bladder Drug Sales by Application (2017-2028)
6.3.2 North America Overactive Bladder Drug Revenue by Application (2017-2028)
6.4 North America Overactive Bladder Drug Market Size by Country
6.4.1 North America Overactive Bladder Drug Sales by Country (2017-2028)
6.4.2 North America Overactive Bladder Drug Revenue by Country (2017-2028)
6.4.3 U.S.
6.4.4 Canada
7 Europe
7.1 Europe Overactive Bladder Drug Sales Breakdown by Company
7.1.1 Europe Overactive Bladder Drug Sales by Company (2017-2022)
7.1.2 Europe Overactive Bladder Drug Revenue by Company (2017-2022)
7.2 Europe Overactive Bladder Drug Market Size by Type
7.2.1 Europe Overactive Bladder Drug Sales by Type (2017-2028)
7.2.2 Europe Overactive Bladder Drug Revenue by Type (2017-2028)
7.3 Europe Overactive Bladder Drug Market Size by Application
7.3.1 Europe Overactive Bladder Drug Sales by Application (2017-2028)
7.3.2 Europe Overactive Bladder Drug Revenue by Application (2017-2028)
7.4 Europe Overactive Bladder Drug Market Size by Country
7.4.1 Europe Overactive Bladder Drug Sales by Country (2017-2028)
7.4.2 Europe Overactive Bladder Drug Revenue by Country (2017-2028)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
8 Asia Pacific
8.1 Asia Pacific Overactive Bladder Drug Sales Breakdown by Company
8.1.1 Asia Pacific Overactive Bladder Drug Sales by Company (2017-2022)
8.1.2 Asia Pacific Overactive Bladder Drug Revenue by Company (2017-2022)
8.2 Asia Pacific Overactive Bladder Drug Market Size by Type
8.2.1 Asia Pacific Overactive Bladder Drug Sales by Type (2017-2028)
8.2.2 Asia Pacific Overactive Bladder Drug Revenue by Type (2017-2028)
8.3 Asia Pacific Overactive Bladder Drug Market Size by Application
8.3.1 Asia Pacific Overactive Bladder Drug Sales by Application (2017-2028)
8.3.2 Asia Pacific Overactive Bladder Drug Revenue by Application (2017-2028)
8.4 Asia Pacific Overactive Bladder Drug Market Size by Region
8.4.1 Asia Pacific Overactive Bladder Drug Sales by Region
8.4.2 Asia Pacific Overactive Bladder Drug Revenue by Region
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 India
8.4.7 Australia
8.4.8 Taiwan
8.4.9 Indonesia
8.4.10 Thailand
8.4.11 Malaysia
8.4.12 Philippines
8.4.13 Vietnam
9 Latin America
9.1 Latin America Overactive Bladder Drug Sales Breakdown by Company
9.1.1 Latin America Overactive Bladder Drug Sales by Company (2017-2022)
9.1.2 Latin America Overactive Bladder Drug Revenue by Company (2017-2022)
9.2 Latin America Overactive Bladder Drug Market Size by Type
9.2.1 Latin America Overactive Bladder Drug Sales by Type (2017-2028)
9.2.2 Latin America Overactive Bladder Drug Revenue by Type (2017-2028)
9.3 Latin America Overactive Bladder Drug Market Size by Application
9.3.1 Latin America Overactive Bladder Drug Sales by Application (2017-2028)
9.3.2 Latin America Overactive Bladder Drug Revenue by Application (2017-2028)
9.4 Latin America Overactive Bladder Drug Market Size by Country
9.4.1 Latin America Overactive Bladder Drug Sales by Country (2017-2028)
9.4.2 Latin America Overactive Bladder Drug Revenue by Country (2017-2028)
9.4.3 Mexico
9.4.4 Brazil
9.4.5 Argentina
10 Middle East and Africa
10.1 Middle East and Africa Overactive Bladder Drug Sales Breakdown by Company
10.1.1 Middle East and Africa Overactive Bladder Drug Sales by Company (2017-2022)
10.1.2 Middle East and Africa Overactive Bladder Drug Revenue by Company (2017-2022)
10.2 Middle East and Africa Overactive Bladder Drug Market Size by Type
10.2.1 Middle East and Africa Overactive Bladder Drug Sales by Type (2017-2028)
10.2.2 Middle East and Africa Overactive Bladder Drug Revenue by Type (2017-2028)
10.3 Middle East and Africa Overactive Bladder Drug Market Size by Application
10.3.1 Middle East and Africa Overactive Bladder Drug Sales by Application (2017-2028)
10.3.2 Middle East and Africa Overactive Bladder Drug Revenue by Application (2017-2028)
10.4 Middle East and Africa Overactive Bladder Drug Market Size by Country
10.4.1 Middle East and Africa Overactive Bladder Drug Sales by Country (2017-2028)
10.4.2 Middle East and Africa Overactive Bladder Drug Revenue by Country (2017-2028)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE
11 Company Profiles
11.1 Astellas Pharma, Inc. (Japan)
11.1.1 Astellas Pharma, Inc. (Japan) Corporation Information
11.1.2 Astellas Pharma, Inc. (Japan) Overview
11.1.3 Astellas Pharma, Inc. (Japan) Overactive Bladder Drug Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2017-2022)
11.1.4 Astellas Pharma, Inc. (Japan) Overactive Bladder Drug Products and Services
11.1.5 Astellas Pharma, Inc. (Japan) Overactive Bladder Drug SWOT Analysis
11.1.6 Astellas Pharma, Inc. (Japan) Recent Developments
11.2 Pfizer, Inc. (US)
11.2.1 Pfizer, Inc. (US) Corporation Information
11.2.2 Pfizer, Inc. (US) Overview
11.2.3 Pfizer, Inc. (US) Overactive Bladder Drug Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2017-2022)
11.2.4 Pfizer, Inc. (US) Overactive Bladder Drug Products and Services
11.2.5 Pfizer, Inc. (US) Overactive Bladder Drug SWOT Analysis
11.2.6 Pfizer, Inc. (US) Recent Developments
11.3 Teva Pharmaceutical Industries Limited (Israel)
11.3.1 Teva Pharmaceutical Industries Limited (Israel) Corporation Information
11.3.2 Teva Pharmaceutical Industries Limited (Israel) Overview
11.3.3 Teva Pharmaceutical Industries Limited (Israel) Overactive Bladder Drug Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2017-2022)
11.3.4 Teva Pharmaceutical Industries Limited (Israel) Overactive Bladder Drug Products and Services
11.3.5 Teva Pharmaceutical Industries Limited (Israel) Overactive Bladder Drug SWOT Analysis
11.3.6 Teva Pharmaceutical Industries Limited (Israel) Recent Developments
11.4 Allergan, Plc (Ireland)
11.4.1 Allergan, Plc (Ireland) Corporation Information
11.4.2 Allergan, Plc (Ireland) Overview
11.4.3 Allergan, Plc (Ireland) Overactive Bladder Drug Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2017-2022)
11.4.4 Allergan, Plc (Ireland) Overactive Bladder Drug Products and Services
11.4.5 Allergan, Plc (Ireland) Overactive Bladder Drug SWOT Analysis
11.4.6 Allergan, Plc (Ireland) Recent Developments
11.5 Medtronic plc (Ireland)
11.5.1 Medtronic plc (Ireland) Corporation Information
11.5.2 Medtronic plc (Ireland) Overview
11.5.3 Medtronic plc (Ireland) Overactive Bladder Drug Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2017-2022)
11.5.4 Medtronic plc (Ireland) Overactive Bladder Drug Products and Services
11.5.5 Medtronic plc (Ireland) Overactive Bladder Drug SWOT Analysis
11.5.6 Medtronic plc (Ireland) Recent Developments
11.6 Mylan N.V. (US)
11.6.1 Mylan N.V. (US) Corporation Information
11.6.2 Mylan N.V. (US) Overview
11.6.3 Mylan N.V. (US) Overactive Bladder Drug Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2017-2022)
11.6.4 Mylan N.V. (US) Overactive Bladder Drug Products and Services
11.6.5 Mylan N.V. (US) Overactive Bladder Drug SWOT Analysis
11.6.6 Mylan N.V. (US) Recent Developments
11.7 Endo International plc (Ireland)
11.7.1 Endo International plc (Ireland) Corporation Information
11.7.2 Endo International plc (Ireland) Overview
11.7.3 Endo International plc (Ireland) Overactive Bladder Drug Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2017-2022)
11.7.4 Endo International plc (Ireland) Overactive Bladder Drug Products and Services
11.7.5 Endo International plc (Ireland) Overactive Bladder Drug SWOT Analysis
11.7.6 Endo International plc (Ireland) Recent Developments
11.8 Hisamitsu Pharmaceutical Co., Inc. (Japan)
11.8.1 Hisamitsu Pharmaceutical Co., Inc. (Japan) Corporation Information
11.8.2 Hisamitsu Pharmaceutical Co., Inc. (Japan) Overview
11.8.3 Hisamitsu Pharmaceutical Co., Inc. (Japan) Overactive Bladder Drug Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2017-2022)
11.8.4 Hisamitsu Pharmaceutical Co., Inc. (Japan) Overactive Bladder Drug Products and Services
11.8.5 Hisamitsu Pharmaceutical Co., Inc. (Japan) Overactive Bladder Drug SWOT Analysis
11.8.6 Hisamitsu Pharmaceutical Co., Inc. (Japan) Recent Developments
11.9 Sanofi (France)
11.9.1 Sanofi (France) Corporation Information
11.9.2 Sanofi (France) Overview
11.9.3 Sanofi (France) Overactive Bladder Drug Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2017-2022)
11.9.4 Sanofi (France) Overactive Bladder Drug Products and Services
11.9.5 Sanofi (France) Overactive Bladder Drug SWOT Analysis
11.9.6 Sanofi (France) Recent Developments
11.10 Apotex, Inc. (Canada)
11.10.1 Apotex, Inc. (Canada) Corporation Information
11.10.2 Apotex, Inc. (Canada) Overview
11.10.3 Apotex, Inc. (Canada) Overactive Bladder Drug Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2017-2022)
11.10.4 Apotex, Inc. (Canada) Overactive Bladder Drug Products and Services
11.10.5 Apotex, Inc. (Canada) Overactive Bladder Drug SWOT Analysis
11.10.6 Apotex, Inc. (Canada) Recent Developments
11.11 Cogentix Medical, Inc. (US)
11.11.1 Cogentix Medical, Inc. (US) Corporation Information
11.11.2 Cogentix Medical, Inc. (US) Overview
11.11.3 Cogentix Medical, Inc. (US) Overactive Bladder Drug Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2017-2022)
11.11.4 Cogentix Medical, Inc. (US) Overactive Bladder Drug Products and Services
11.11.5 Cogentix Medical, Inc. (US) Recent Developments
11.12 Aurobindo Pharma Limited (India)
11.12.1 Aurobindo Pharma Limited (India) Corporation Information
11.12.2 Aurobindo Pharma Limited (India) Overview
11.12.3 Aurobindo Pharma Limited (India) Overactive Bladder Drug Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2017-2022)
11.12.4 Aurobindo Pharma Limited (India) Overactive Bladder Drug Products and Services
11.12.5 Aurobindo Pharma Limited (India) Recent Developments
12 Value Chain and Sales Channels Analysis
12.1 Overactive Bladder Drug Value Chain Analysis
12.2 Overactive Bladder Drug Key Raw Materials
12.2.1 Key Raw Materials
12.2.2 Raw Materials Key Suppliers
12.3 Overactive Bladder Drug Production Mode & Process
12.4 Overactive Bladder Drug Sales and Marketing
12.4.1 Overactive Bladder Drug Sales Channels
12.4.2 Overactive Bladder Drug Distributors
12.5 Overactive Bladder Drug Customers
13 Research Findings and Conclusion
14 Appendix
14.1 Research Methodology
14.1.1 Methodology/Research Approach
14.1.2 Data Source
14.2 Author Details
14.3 Disclaimer
List of Tables
Table 1. Global Overactive Bladder Drug Market Size Growth Rate by Type, 2017 VS 2021 VS 2028 (US$ Million)
Table 2. Major Manufacturers of Anticholinergics
Table 3. Major Manufacturers of Solifenacin
Table 4. Major Manufacturers of Oxybutynin
Table 5. Major Manufacturers of Darifenacin
Table 6. Major Manufacturers of Fesoterodine
Table 7. Major Manufacturers of Tolterodine
Table 8. Major Manufacturers of Trospium
Table 9. Major Manufacturers of Others
Table 10. Global Overactive Bladder Drug Market Size Growth Rate by Application, 2017 VS 2021 VS 2028 (US$ Million)
Table 11. Global Overactive Bladder Drug Market Size (US$ Million) by Region: 2017 VS 2021 VS 2028
Table 12. Global Overactive Bladder Drug Sales by Region (2017-2022) & (K Units)
Table 13. Global Overactive Bladder Drug Sales Market Share by Region (2017-2022)
Table 14. Global Overactive Bladder Drug Revenue by Region (2017-2022) & (US$ Million)
Table 15. Global Overactive Bladder Drug Revenue Market Share by Region (2017-2022)
Table 16. Global Overactive Bladder Drug Sales Forecast by Region (2023-2028) & (K Units)
Table 17. Global Overactive Bladder Drug Sales Market Share Forecast by Region (2023-2028)
Table 18. Global Overactive Bladder Drug Revenue Forecast by Region (2023-2028) & (US$ Million)
Table 19. Global Overactive Bladder Drug Revenue Market Share Forecast by Region (2023-2028)
Table 20. Top Overactive Bladder Drug Regions (Countries) Ranking by Market Size (US$ Million) in 2021
Table 21. Overactive Bladder Drug Market Trends
Table 22. Overactive Bladder Drug Market Drivers
Table 23. Overactive Bladder Drug Market Challenges
Table 24. Overactive Bladder Drug Market Restraints
Table 25. Global Overactive Bladder Drug Sales by Manufacturers (2017-2022) & (K Units)
Table 26. Global Overactive Bladder Drug Sales Share by Manufacturers (2017-2022)
Table 27. Global Overactive Bladder Drug Revenue by Manufacturers (2017-2022) & (US$ Million)
Table 28. Ranking of Global Top Overactive Bladder Drug Manufacturers by Revenue (US$ Million) in 2021
Table 29. Overactive Bladder Drug Revenue Share by Manufacturers (2017-2022)
Table 30. Global Overactive Bladder Drug Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 31. Global Top Manufacturers Market Share by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Overactive Bladder Drug as of 2021)
Table 32. Key Manufacturers Overactive Bladder Drug Average Selling Price (ASP) & (2017-2022) & (USD/Unit)
Table 33. Key Manufacturers Overactive Bladder Drug Plants/Factories Distribution
Table 34. Key Manufacturers Overactive Bladder Drug Area Served
Table 35. Date of Key Manufacturers Enter into Overactive Bladder Drug Market
Table 36. Key Manufacturers Overactive Bladder Drug Product Type
Table 37. Mergers & Acquisitions, Expansion Plans
Table 38. Global Overactive Bladder Drug Sales (K Units) by Type (2017-2022)
Table 39. Global Overactive Bladder Drug Sales Share by Type (2017-2022)
Table 40. Global Overactive Bladder Drug Revenue (US$ Million) Market Share by Type (2017-2022)
Table 41. Global Overactive Bladder Drug Price (K Units) by Type (2017-2022)
Table 42. Global Overactive Bladder Drug Sales (K Units) by Type (2023-2028)
Table 43. Global Overactive Bladder Drug Sales Share by Type (2023-2028)
Table 44. Global Overactive Bladder Drug Revenue (US$ Million) Market Share by Type (2023-2028)
Table 45. Global Overactive Bladder Drug Revenue Share by Type (2023-2028)
Table 46. Global Overactive Bladder Drug Price (K Units) by Type (2023-2028)
Table 47. Global Overactive Bladder Drug Sales (K Units) by Application (2017-2022)
Table 48. Global Overactive Bladder Drug Sales Share by Application (2017-2022)
Table 49. Global Overactive Bladder Drug Revenue (US$ Million) Market Share by Application (2017-2022)
Table 50. Global Overactive Bladder Drug Price (K Units) by Application (2017-2022)
Table 51. Global Overactive Bladder Drug Sales (K Units) by Application (2023-2028)
Table 52. Global Overactive Bladder Drug Sales Share by Application (2023-2028)
Table 53. Global Overactive Bladder Drug Revenue (US$ Million) Market Share by Application (2023-2028)
Table 54. Global Overactive Bladder Drug Revenue Share by Application (2023-2028)
Table 55. Global Overactive Bladder Drug Price (K Units) by Application (2023-2028)
Table 56. North America Overactive Bladder Drug Sales by Company (2017-2022) & (K Units)
Table 57. North America Overactive Bladder Drug Sales Market Share by Company (2017-2022)
Table 58. North America Overactive Bladder Drug Revenue by Company (2017-2022) & (US$ Million)
Table 59. North America Overactive Bladder Drug Revenue Market Share by Company (2017-2022)
Table 60. North America Overactive Bladder Drug Sales by Type (2017-2022) & (K Units)
Table 61. North America Overactive Bladder Drug Sales by Type (2023-2028) & (K Units)
Table 62. North America Overactive Bladder Drug Revenue by Type (2017-2022) & (US$ Million)
Table 63. North America Overactive Bladder Drug Revenue by Type (2023-2028) & (US$ Million)
Table 64. North America Overactive Bladder Drug Sales by Application (2017-2022) & (K Units)
Table 65. North America Overactive Bladder Drug Sales by Application (2023-2028) & (K Units)
Table 66. North America Overactive Bladder Drug Revenue by Application (2017-2022) & (US$ Million)
Table 67. North America Overactive Bladder Drug Revenue by Application (2023-2028) & (US$ Million)
Table 68. North America Overactive Bladder Drug Sales by Country (2017-2022) & (K Units)
Table 69. North America Overactive Bladder Drug Sales by Country (2023-2028) & (K Units)
Table 70. North America Overactive Bladder Drug Revenue by Country (2017-2022) & (US$ Million)
Table 71. North America Overactive Bladder Drug Revenue by Country (2023-2028) & (US$ Million)
Table 72. Europe Overactive Bladder Drug Sales by Company (2017-2022) & (K Units)
Table 73. Europe Overactive Bladder Drug Sales Market Share by Company (2017-2022)
Table 74. Europe Overactive Bladder Drug Revenue by Company (2017-2022) & (US$ Million)
Table 75. Europe Overactive Bladder Drug Revenue Market Share by Company (2017-2022)
Table 76. Europe Overactive Bladder Drug Sales by Type (2017-2022) & (K Units)
Table 77. Europe Overactive Bladder Drug Sales by Type (2023-2028) & (K Units)
Table 78. Europe Overactive Bladder Drug Revenue by Type (2017-2022) & (US$ Million)
Table 79. Europe Overactive Bladder Drug Revenue by Type (2023-2028) & (US$ Million)
Table 80. Europe Overactive Bladder Drug Sales by Application (2017-2022) & (K Units)
Table 81. Europe Overactive Bladder Drug Sales by Application (2023-2028) & (K Units)
Table 82. Europe Overactive Bladder Drug Revenue by Application (2017-2022) & (US$ Million)
Table 83. Europe Overactive Bladder Drug Revenue by Application (2023-2028) & (US$ Million)
Table 84. Europe Overactive Bladder Drug Sales by Country (2017-2022) & (K Units)
Table 85. Europe Overactive Bladder Drug Sales by Country (2023-2028) & (K Units)
Table 86. Europe Overactive Bladder Drug Revenue by Country (2017-2022) & (US$ Million)
Table 87. Europe Overactive Bladder Drug Revenue by Country (2023-2028) & (US$ Million)
Table 88. Asia Pacific Overactive Bladder Drug Sales by Company (2017-2022) & (K Units)
Table 89. Asia Pacific Overactive Bladder Drug Sales Market Share by Company (2017-2022)
Table 90. Asia Pacific Overactive Bladder Drug Revenue by Company (2017-2022) & (US$ Million)
Table 91. Asia Pacific Overactive Bladder Drug Revenue Market Share by Company (2017-2022)
Table 92. Asia Pacific Overactive Bladder Drug Sales by Type (2017-2022) & (K Units)
Table 93. Asia Pacific Overactive Bladder Drug Sales by Type (2023-2028) & (K Units)
Table 94. Asia Pacific Overactive Bladder Drug Revenue by Type (2017-2022) & (US$ Million)
Table 95. Asia Pacific Overactive Bladder Drug Revenue by Type (2023-2028) & (US$ Million)
Table 96. Asia Pacific Overactive Bladder Drug Sales by Application (2017-2022) & (K Units)
Table 97. Asia Pacific Overactive Bladder Drug Sales by Application (2023-2028) & (K Units)
Table 98. Asia Pacific Overactive Bladder Drug Revenue by Application (2017-2022) & (US$ Million)
Table 99. Asia Pacific Overactive Bladder Drug Revenue by Application (2023-2028) & (US$ Million)
Table 100. Asia Pacific Overactive Bladder Drug Sales by Region (2017-2022) & (K Units)
Table 101. Asia Pacific Overactive Bladder Drug Sales by Region (2023-2028) & (K Units)
Table 102. Asia Pacific Overactive Bladder Drug Revenue by Region (2017-2022) & (US$ Million)
Table 103. Asia Pacific Overactive Bladder Drug Revenue by Region (2023-2028) & (US$ Million)
Table 104. Latin America Overactive Bladder Drug Sales by Company (2017-2022) & (K Units)
Table 105. Latin America Overactive Bladder Drug Sales Market Share by Company (2017-2022)
Table 106. Latin America Overactive Bladder Drug Revenue by Company (2017-2022) & (US$ Million)
Table 107. Latin America Overactive Bladder Drug Revenue Market Share by Company (2017-2022)
Table 108. Latin America Overactive Bladder Drug Sales by Type (2017-2022) & (K Units)
Table 109. Latin America Overactive Bladder Drug Sales by Type (2023-2028) & (K Units)
Table 110. Latin America Overactive Bladder Drug Revenue by Type (2017-2022) & (US$ Million)
Table 111. Latin America Overactive Bladder Drug Revenue by Type (2023-2028) & (US$ Million)
Table 112. Latin America Overactive Bladder Drug Sales by Application (2017-2022) & (K Units)
Table 113. Latin America Overactive Bladder Drug Sales by Application (2023-2028) & (K Units)
Table 114. Latin America Overactive Bladder Drug Revenue by Application (2017-2022) & (US$ Million)
Table 115. Latin America Overactive Bladder Drug Revenue by Application (2023-2028) & (US$ Million)
Table 116. Latin America Overactive Bladder Drug Sales by Country (2017-2022) & (K Units)
Table 117. Latin America Overactive Bladder Drug Sales by Country (2023-2028) & (K Units)
Table 118. Latin America Overactive Bladder Drug Revenue by Country (2017-2022) & (US$ Million)
Table 119. Latin America Overactive Bladder Drug Revenue by Country (2023-2028) & (US$ Million)
Table 120. Middle East and Africa Overactive Bladder Drug Sales by Company (2017-2022) & (K Units)
Table 121. Middle East and Africa Overactive Bladder Drug Sales Market Share by Company (2017-2022)
Table 122. Middle East and Africa Overactive Bladder Drug Revenue by Company (2017-2022) & (US$ Million)
Table 123. Middle East and Africa Overactive Bladder Drug Revenue Market Share by Company (2017-2022)
Table 124. Middle East and Africa Overactive Bladder Drug Sales by Type (2017-2022) & (K Units)
Table 125. Middle East and Africa Overactive Bladder Drug Sales by Type (2023-2028) & (K Units)
Table 126. Middle East and Africa Overactive Bladder Drug Revenue by Type (2017-2022) & (US$ Million)
Table 127. Middle East and Africa Overactive Bladder Drug Revenue by Type (2023-2028) & (US$ Million)
Table 128. Middle East and Africa Overactive Bladder Drug Sales by Application (2017-2022) & (K Units)
Table 129. Middle East and Africa Overactive Bladder Drug Sales by Application (2023-2028) & (K Units)
Table 130. Middle East and Africa Overactive Bladder Drug Revenue by Application (2017-2022) & (US$ Million)
Table 131. Middle East and Africa Overactive Bladder Drug Revenue by Application (2023-2028) & (US$ Million)
Table 132. Middle East and Africa Overactive Bladder Drug Sales by Country (2017-2022) & (K Units)
Table 133. Middle East and Africa Overactive Bladder Drug Sales by Country (2023-2028) & (K Units)
Table 134. Middle East and Africa Overactive Bladder Drug Revenue by Country (2017-2022) & (US$ Million)
Table 135. Middle East and Africa Overactive Bladder Drug Revenue by Country (2023-2028) & (US$ Million)
Table 136. Astellas Pharma, Inc. (Japan) Corporation Information
Table 137. Astellas Pharma, Inc. (Japan) Description and Overview
Table 138. Astellas Pharma, Inc. (Japan) Overactive Bladder Drug Sales (K Units), Revenue (US$ Million), Average Selling Price (ASP) (USD/Unit) and Gross Margin (2017-2022)
Table 139. Astellas Pharma, Inc. (Japan) Overactive Bladder Drug Product and Services
Table 140. Astellas Pharma, Inc. (Japan) Overactive Bladder Drug SWOT Analysis
Table 141. Astellas Pharma, Inc. (Japan) Recent Developments
Table 142. Pfizer, Inc. (US) Corporation Information
Table 143. Pfizer, Inc. (US) Description and Overview
Table 144. Pfizer, Inc. (US) Overactive Bladder Drug Sales (K Units), Revenue (US$ Million), Average Selling Price (ASP) (USD/Unit) and Gross Margin (2017-2022)
Table 145. Pfizer, Inc. (US) Overactive Bladder Drug Product and Services
Table 146. Pfizer, Inc. (US) Overactive Bladder Drug SWOT Analysis
Table 147. Pfizer, Inc. (US) Recent Developments
Table 148. Teva Pharmaceutical Industries Limited (Israel) Corporation Information
Table 149. Teva Pharmaceutical Industries Limited (Israel) Description and Overview
Table 150. Teva Pharmaceutical Industries Limited (Israel) Overactive Bladder Drug Sales (K Units), Revenue (US$ Million), Average Selling Price (ASP) (USD/Unit) and Gross Margin (2017-2022)
Table 151. Teva Pharmaceutical Industries Limited (Israel) Overactive Bladder Drug Product and Services
Table 152. Teva Pharmaceutical Industries Limited (Israel) Overactive Bladder Drug SWOT Analysis
Table 153. Teva Pharmaceutical Industries Limited (Israel) Recent Developments
Table 154. Allergan, Plc (Ireland) Corporation Information
Table 155. Allergan, Plc (Ireland) Description and Overview
Table 156. Allergan, Plc (Ireland) Overactive Bladder Drug Sales (K Units), Revenue (US$ Million), Average Selling Price (ASP) (USD/Unit) and Gross Margin (2017-2022)
Table 157. Allergan, Plc (Ireland) Overactive Bladder Drug Product and Services
Table 158. Allergan, Plc (Ireland) Overactive Bladder Drug SWOT Analysis
Table 159. Allergan, Plc (Ireland) Recent Developments
Table 160. Medtronic plc (Ireland) Corporation Information
Table 161. Medtronic plc (Ireland) Description and Overview
Table 162. Medtronic plc (Ireland) Overactive Bladder Drug Sales (K Units), Revenue (US$ Million), Average Selling Price (ASP) (USD/Unit) and Gross Margin (2017-2022)
Table 163. Medtronic plc (Ireland) Overactive Bladder Drug Product and Services
Table 164. Medtronic plc (Ireland) Overactive Bladder Drug SWOT Analysis
Table 165. Medtronic plc (Ireland) Recent Developments
Table 166. Mylan N.V. (US) Corporation Information
Table 167. Mylan N.V. (US) Description and Overview
Table 168. Mylan N.V. (US) Overactive Bladder Drug Sales (K Units), Revenue (US$ Million), Average Selling Price (ASP) (USD/Unit) and Gross Margin (2017-2022)
Table 169. Mylan N.V. (US) Overactive Bladder Drug Product and Services
Table 170. Mylan N.V. (US) Overactive Bladder Drug SWOT Analysis
Table 171. Mylan N.V. (US) Recent Developments
Table 172. Endo International plc (Ireland) Corporation Information
Table 173. Endo International plc (Ireland) Description and Overview
Tab

• Clinical Results in Diabetics To Be Boosted By Smart Artificial Beta Cells

For a long time, the cure for diabetes type 1 and type 2 has relied on agonizing insulin shots for patients or insulin infusion via mechanical pumps. Regarding this, experts have been creating artificial pancreatic beta cells with the he…

• High-speed Data Transmission And High Volume Needs Propel Fiber Optic Connectors Market

Fiber optic connectors are a substantial fragment of the global telecommunication industry. Optical fibers are joined using fiber optic connectors, which allow the light conduction between two consecutive optical fibers. An additional im…

• Extensive Use of Digital Technologies for Diagnostic Applications To Boost Global Optical Imaging Market

The global optical imaging system market is predicted to reach US$ 3 billion by 2024. It is expected to grow at a stable rate and will post a CAGR of more than 8% in the coming years. The growing market infiltration of digital …

• Foremost Trends In Global Pet Care Market

The global pet care market is foretold to improve in the forthcoming years as matched to the preceding years and will showcase better sales in various market segments. It is estimated that the global pet care market will grow at a CAGR o…

• China To Review Its Food Security Laws

China has arisen as the globe’s firmest developing economy. In addition, China brags about the biggest population pool in the world. In recent times, the one child policy in the republic was terminated. This is anticipated to upsur…

Global Antioxidant Vitamins Market Research Report 2024

Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 100

The global Antioxidant Vitamins market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during The forecast period 2024-2030. North American market for Antioxidant Vitamins is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030. Asia-Pacific market for Antioxidant Vitamins is estimated to increase from $ million in 2023 to reach $ millio......

Global Clavulanate Potassium Market Research Report 2024

Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 86

The global Clavulanate Potassium market was valued at US$ 446.6 million in 2023 and is anticipated to reach US$ 637.2 million by 2030, witnessing a CAGR of 5.2% during The forecast period 2024-2030. North American market for Clavulanate Potassium is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030. Asia-Pacific market for Clavulanate Potassium is estimated to increase from $ million in 2023......

Global Amoxicillin Sodium Market Research Report 2024

Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 84

The global Amoxicillin Sodium market was valued at US$ 460.9 million in 2023 and is anticipated to reach US$ 735.1 million by 2030, witnessing a CAGR of 7.0% during The forecast period 2024-2030. North American market for Amoxicillin Sodium is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030. Asia-Pacific market for Amoxicillin Sodium is estimated to increase from $ million in 2023 to reach......

Global Melatonin Supplements Market Research Report 2024

Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 106

The global Melatonin Supplements market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during The forecast period 2024-2030. North American market for Melatonin Supplements is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030. Asia-Pacific market for Melatonin Supplements is estimated to increase from $ million in 2023 to reach $ mil......

Global Sleeping Pills (Prescription Drugs) Market Research Report 2024

Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 93

The global Sleeping Pills (Prescription Drugs) market was valued at US$ 1022.3 million in 2023 and is anticipated to reach US$ 1437.8 million by 2030, witnessing a CAGR of 4.9% during The forecast period 2024-2030. The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during The next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, The chemical......

Global Sleeping Pills Market Research Report 2024

Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 94

The global Sleeping Pills market was valued at US$ 2042.3 million in 2023 and is anticipated to reach US$ 2979.5 million by 2030, witnessing a CAGR of 3.8% during The forecast period 2024-2030. The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during The next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, The chemical drug market is estim......

Global Zinc Oral Drops Market Research Report 2024

Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 85

The global Zinc Oral Drops market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during The forecast period 2024-2030. North American market for Zinc Oral Drops is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030. Asia-Pacific market for Zinc Oral Drops is estimated to increase from $ million in 2023 to reach $ million by 2030, at a......

Global Zinc Drops Market Research Report 2024

Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 85

The global Zinc Drops market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during The forecast period 2024-2030. North American market for Zinc Drops is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030. Asia-Pacific market for Zinc Drops is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % duri......

Global Anti-Infectives Market Research Report 2024

Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 78

The global Anti-Infectives market was valued at US$ 22700 million in 2023 and is anticipated to reach US$ 27480 million by 2030, witnessing a CAGR of 2.3% during The forecast period 2024-2030. The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during The next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, The chemical drug market is estima......

We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s. Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors. Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business. Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision. Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us. Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done. Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - [email protected] / +1 888 391 5441 )

• Ad Hoc
• Pay - as - you - go / Bucket Subscriptions
• Fixed Cost for #of reports
• Customize / Personalize as per your needs